Adrenoleukodystrophy
📧 Sign up to get email alerts when something new happens for Adrenoleukodystrophy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2024-12-16Clinical Trial Update: Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD) [Phase 2]
Phase 2 trial of PXL065 for adrenomyeloneuropathy (AMN), a form of X-linked adrenoleukodystrophy, has been withdrawn.
-
EMA withdrawal · 2024-11-20EMA Refused: Nezglyal (leriglitazone hydrochloride) — Minoryx Therapeutics S.L.
The EMA refused to grant marketing authorization for Nezglyal (leriglitazone hydrochloride) for the treatment of adrenoleukodystrophy, under…
-
EMA withdrawal · 2022-04-04EMA Withdrawn: Skysona (elivaldogene autotemcel) — bluebird bio (Netherlands) B.V.
EMA has withdrawn Skysona (elivaldogene autotemcel) from the market in the Netherlands for adrenoleukodystrophy.
-
CLINICAL_TRIALS withdrawal · 2018-07-06Clinical Trial Update: Early Diagnosis Of Childhood Cerebral ALD
A clinical trial investigating early diagnosis of childhood cerebral adrenoleukodystrophy has been withdrawn from the registry. The record d…